

First North Announcement no. 14 2007/ August 27th, 2007

Copenhagen, August 27th, 2007

Summary: The authorities in Serbia and Denmark have now approved the requests for conducting open deliberate release with gene modified Thale Cress.

The plant based biotech company Aresa made an application to the authorities in Serbia about deliberate release involving open air trials with gene modified Thale Cress. Thale Cress (*Arabidopsis Thaliana*) is to be used for detection of explosives in soil among other in landmines. The Serbian authorities has evaluated and approved Aresa's application according to local GMO -legislation.

The deliberate release will take place in an area close to Novi Sad in Serbia, and will be conducted in cooperation with the agricultural institute NS Seme in Novi Sad, (See First North announcement #9). The trials will commence immediately and will continue until end of the current growth season. In order to maximize the outcome of the deliberate release the trials will also involve seeding of various eco-types of Thale Cress. In parallel a similar approval has been given by Skov- og Naturstyrelsen in Denmark for a deliberate release in Jægerspris (Denmark).

"The approval is an important milestone in Aresa's further development of the landmine detection plant RedDetect™. It is important to Aresa to be able to test the plants outside Denmark, and more importantly in an area, where landmines do occur and soil conditions are similar to where we potentially are going to detect landmines and other explosives. We are taking yet another step towards fulfilling our objective to form a strong plant based bio-tech company" states Ole Andersen, chairman of the board.

As an important next step, Aresa expects during the spring of 2008 to have transferred the RedDetect™ technology to the tobacco plant (Petit Havana), in order to improve the robustness of RedDetect™ as well as the commercial potential. NS Seme in Novi Sad has significant expertise related to growing and refining tobacco plants.

The content of this message is not expected to have impact on the result for the current financial year.

Best regards,

Ole Andersen
Chairman
Aresa A/S

Further information can be obtained by contacting Ole Andersen, Chairman for Aresa A/S on +45 70227747 or +45 40580214 or to the company's financial advisor HSH Corporate Finance A/S, Morten Kjærulff, Director, +45 33449431.

About Aresa

Aresa is a plant biotech company established in 2001 by the company's current CSO, Carsten Meier and has origins from the Institute of Molecular Biology at Copenhagen University.

Aresa has developed two plant based technology platforms, BioSensor for the detection of substances in soil, hereunder evaporation of explosives from landmines; and BioPharma, a tool for the optimisation and production of antibodies and proteins in plants.

Aresa was listed on the Copenhagen OMX-First North market place in 2006. Aresa is based at Symbion Science Park in Copenhagen and has greenhouse facilities in the outskirts of Copenhagen and test areas in Denmark, Croatia and Serbia. Aresa has 16 employees, hereof 8 within research and development and 5 within landmine operations.

First North meddelelse nr. 14 2007 /27. august 2007

Aresa A/S – CVR-nr. 26058651
Symbion Science Park
Fruebjergvej 3
2100 København Ø
www.aresa.dk